

Special Issue on
**New Insights into *Helicobacter pylori* Infection: Treatment
Strategies**

CALL FOR PAPERS

Helicobacter pylori (*Hp*) is involved in a wide variety of infections such as chronic active gastritis, peptic ulcer disease, gastric carcinoma, and mucosa-associated lymphoid tissue lymphoma (MALT) as well as endothelial dysfunction leading to vascular diseases. It is spreading all over the world mostly in developing countries and is life-long in the absence of specific treatments.

Unfortunately, the prevalence of antibiotic resistance has become increasingly widespread in the last decade especially for metronidazole and clarithromycin once considered the antibiotics of choice. Mainly clarithromycin resistance (less or more than 15%) is considered discriminant in addressing a correct therapy.

The heteroresistance (simultaneous presence of both susceptible and resistant strains in different sites of a single stomach) is another important drawback misclassifying an isolate as susceptible if a biopsy of only one district (antrum, corpus, or fundus) was used for antimicrobial tests in such a way missing the resistant microorganisms with consequent treatment failure.

Thus, considering that the old triple therapy as well as other therapy schemes is currently obsolete, it is crucial to identify the effective treatments capable of curing *Hp* infection searching for the best options to eradicate this pathogen especially for those containing bismuth that ensure both patients' compliance and the fewest side effects.

In this challenging scenario, the aim of this issue is to attract review articles as well as original research articles in order to find new suitable therapeutic strategies containing different associations of antibiotics that may be more recommended for the patients or to test new drugs and rescue treatments or nontraditional therapies.

Potential topics include but are not limited to the following:

- ▶ *In vitro* study of antimicrobial activity of plants, probiotics, and polysaccharides
- ▶ Detection of nontraditional therapies in order to target this important gastric pathogen such as the use of antimicrobial peptides (AMPs) (core component of innate immune system of numerous eukaryotes)
- ▶ Investigation of other options aimed at reinforcing the immune system of patients with *Hp* infection
- ▶ Influence of the heteroresistance in the treatment failure and molecular studies of the genotypes involved in this phenomenon
- ▶ Usefulness of susceptibility tests *in vitro* for the establishment of a correct antibiotic therapy
- ▶ Different impact between empiric therapies and susceptibility-based therapies
- ▶ Evaluation of the crucial importance of the local antibiotic resistance in a determinate country for the therapy formulation
- ▶ Study of the activity of a new drug (vonoprazan) mainly in CLA-resistant strains
- ▶ Investigation of particular techniques able to make the antibiotics in use more effective even in a strongly acid environment
- ▶ Evaluation of the efficacy of bismuth quadruple therapy even in the first-line regimens

Authors can submit their manuscripts through the Manuscript Tracking System at <https://mts.hindawi.com/submit/journals/cjidmm/nihp/>.

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor

Maria T. Mascellino, Sapienza
University of Rome, Rome, Italy
mariateresa.mascellino@uniroma1.it

Guest Editors

Carola Severi, Sapienza University of
Rome, Rome, Italy
carola.severi@uniroma1.it

Tim Sandle, University of Manchester,
Manchester, UK
tim.sandle@bpl.co.uk

K.H. Ramesh, Montefiore Medical
Center, New York, USA
kramesh@montefiore.org

Submission Deadline

Friday, 7 September 2018

Publication Date

January 2019